FDA OKs Neurostimulation Device for Opioid Withdrawal

Article

DyAnsys Inc. announced that its auricular neurostimulation device, Drug Relief, received clearance from the FDA.

DyAnsys Inc. announced that its auricular neurostimulation device, Drug Relief, received clearance from the FDA. The device is a non-narcotic option to aid in alleviating opioid withdrawal symptoms.

"This device offers hope to those who are suffering from opioid addiction," said DyAnsys Chief Executive Officer Srini Nageshwar, a graduate of the Institute of Technology Madras.

Drug Relief sends electrical pulses through fine needles inserted in the ear over the course of 120 hours. The device stimulates the percutaneous electrical nerve field to reduce symptoms including anxiety, agitation, depression, nausea, and opiate cravings, and increase comfort and mobility for the patient.

Click to continue reading on MD Magazine.

Related Videos
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Mayo Clinic oncology pharmacy
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
A panel of 3 experts on hepatic encephalopathy
A panel of 3 experts on hepatic encephalopathy
A panel of 5 experts on ASCVD
© 2024 MJH Life Sciences

All rights reserved.